Key points are not available for this paper at this time.
Editorial on cath lab billing incentives; leaves open how to realign reimbursement with evidence-based care.
Dr. Andrew M. Goldsweig reports grant support from the National Institute of General Medical Sciences, 1U54GM115458, and the UNMC Center for Heart and Vascular Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Dr. Eric Secemsky is supported in part by NIH/NHLBI K23HL150290 grant. He receives research support from AstraZeneca, BD, Boston Scientific, Cook, CSI, Laminate Medical, Medtronic, and Philips. He receives consulting fees from Abbott, Bayer, BD, Boston Scientific, Cook, CSI, Inari, Janssen, Medtronic, Philips, and VentureMed. Dr. Rishi Wadhera receives research support from the NIH/NHLBI (K23HL148525) and serves as a consultant to Abbott. Dr. David J. Cohen reports research grant support from Abbott, Edwards Life Sciences, Boston Scientific, Medtronic, Svelte, and Corvia; consulting income from Abbott, Edwards Life Sciences, Boston Scientific, Medtronic, Svelte, Corvia, Philips, Impulse Dynamics, and MyoKardia.
No takes yet. Share an insight, caveat, or question.
Goldsweig et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: